MedWatch

Lundbeck carries on Rexulti study after new analysis

After having received a new interim analysis, Lundbeck and its partner Otsuka have decided to keep going with a phase III study with the drug Rexulti for treating Alzheimer's symptoms.

Photo: Jens Dresling

Danish pharmaceutical company Lundbeck and its partner Japanese pharmaceutical firm Otsuka have long been anticipating the results of their phase III trial with Rexulti, or brexpiprazole, for treating agitation in patients suffering from the dementia disease Alzheimer's.

Now, some of the results have been unveiled.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs